Cytokinetics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Cytokinetics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CYTK

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. 

CEO
Robert I. Blum
CEORobert I. Blum
Employees
673
Employees673
Headquarters
South San Francisco, California
HeadquartersSouth San Francisco, California
Founded
1997
Founded1997
Employees
673
Employees673

CYTK Key Statistics

Market cap
7.80B
Market cap7.80B
Price-Earnings ratio
-9.70
Price-Earnings ratio-9.70
Dividend yield
Dividend yield
Average volume
55.88K
Average volume55.88K
High today
$65.29
High today$65.29
Low today
$62.69
Low today$62.69
Open price
$64.01
Open price$64.01
Volume
2.44M
Volume2.44M
52 Week high
$70.89
52 Week high$70.89
52 Week low
$29.35
52 Week low$29.35

Stock Snapshot

With a market cap of 7.8B, Cytokinetics(CYTK) trades at $63.35. The stock has a price-to-earnings ratio of -9.70.

During the trading session on 2026-05-04, Cytokinetics(CYTK) shares reached a daily high of $65.29 and a low of $62.69. At a current price of $63.35, the stock is +1.1% higher than the low and still -3.0% under the high.

Trading volume for Cytokinetics(CYTK) stock has reached 2.44M, versus its average volume of 55.88K.

Over the past 52 weeks, Cytokinetics(CYTK) stock has traded between a high of $70.89 and a low of $29.35.

Over the past 52 weeks, Cytokinetics(CYTK) stock has traded between a high of $70.89 and a low of $29.35.

CYTK News

Simply Wall St 5h
Will Analyst Upgrades After Myqorzo Approval Reshape Cytokinetics' Risk‑Reward Narrative?

Recently, Cytokinetics saw its fair value estimates revised higher by several research firms following the approval of Myqorzo and preparations for the ACACIA n...

Will Analyst Upgrades After Myqorzo Approval Reshape Cytokinetics' Risk‑Reward Narrative?
TipRanks 2d
Western Union, Cytokinetics, Comfort Systems, Albertsons, ASE Shocker

Insiders have been trading these 5 stocks: ((WU)), ((CYTK)), ((FIX)), ((ACI)) and ((ASX)). Here is a breakdown of their recent trades and their value. Unlock h...

TipRanks 3d
Top Cytokinetics Executive Makes Major Move With Insider Stock Sale

New insider activity at Cytokinetics ( (CYTK) ) has taken place on April 30, 2026. Unlock hedge fund-level data and powerful investing tools for smarter, sharp...

Analyst ratings

86%

of 22 ratings
Buy
86.4%
Hold
13.6%
Sell
0%

More CYTK News

Investing.com 4d
Cytokinetics president & CEO Robert Blum sells $447k in shares - Investing.com

...

Cytokinetics president & CEO Robert Blum sells $447k in shares - Investing.com

People also own

Based on the portfolios of people who own CYTK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.